Skip Navigation

Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program

Blog

Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program

Authored by Alan J. Arville, J.D. and Kala K. Shankle, J.D.of Epstein Becker Green In…

Blog

Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings.

Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings. By Hannah Kanfer BluesightⓇ …

Blog

What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital?

What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital? By: Sandy Still, PharmD…

Blog

Drug Shortages, Variance Spikes and Other Key Takeaways from the Diversion Quarterly.

By Hannah Kanfer   BluesightⓇ released the Q2 2022 Diversion Quarterly, sharing data from its…

Blog

Why a Next-Generation Drug Diversion Solution is Vital for Hospitals.

By: Doug Zurawski, Pharm.D.   Drug diversion is any act or deviation that removes a…

Blog

The Pandemic’s Continued Strain On Labor And Other Key Takeaways From The Diversion Trends Report

Kit Check recently released its 2022 Diversion Trends Report. In the report, Kit Check analyzed…

Blog

KitCheck™ Releases New Medication Pricing Information Function as First Step Towards Further Product Integration.

By Hannah Kanfer KitCheck recently released a new feature that integrates medication pricing information into…

Blog

New Bill Will Help Prevent Opioid Deaths by Making Opioid Overdose Medications More Accessible. 

By Hannah Kanfer   The opioid epidemic has been a long battle in the United…

Blog

Early Recognition and Culture of Safety, both Vital to Catching and Preventing Diversion.

Bluesight’s top takeaways from NADDI 2022. By Hannah Kanfer This past week, BluesightⓇ attended the…

Blog

The Evolution of 340B and the Challenges it Faces; is Technology the Answer?

The Evolution of 340B and the Challenges it Faces; is Technology the Answer?  By Hannah…

1 of 15